Twist Bioscience Corporation (TWST)
Stock Price:
$54.71 USD
-1.52 (-2.70%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
2.43B |
| Revenue (ttm) |
65.80M |
| Net Income (ttm) |
-146.50M |
| Shares Out |
44.46M |
| EPS (ttm) |
-4.41 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 10, 2020 |
| Last Price |
$54.71 |
| Previous Close |
$56.23 |
| Change ($) |
-1.52 |
| Change (%) |
-2.70% |
| Day's Open |
56.00 |
| Day's Range |
54.36 - 57.13 |
| Day's Volume |
375,208 |
| 52-Week Range |
18.52 - 57.33 |
More Stats
| Market Cap |
2.43B |
| Enterprise Value |
2.24B |
| Earnings Date (est) |
Jul 30, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
44.46M |
| Float |
32.97M |
| EPS (basic) |
-4.41 |
| EPS (diluted) |
-4.41 |
| FCF / Share |
-4.11 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.82M |
| Short Ratio |
6.91 |
| Short % of Float |
11.33% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
36.97 |
| PB Ratio |
9.19 |
| Revenue |
65.80M |
| Operating Income |
-147.61M |
| Net Income |
-146.50M |
| Free Cash Flow |
-152.86M |
| Net Cash |
189.59M |
| Net Cash / Share |
4.26 |
| Gross Margin |
10.58% |
| Operating Margin |
-224.33% |
| Profit Margin |
-222.70% |
| FCF Margin |
-232.33% |
| ROA |
-33.70% |
| ROE |
-77.17% |
| ROIC |
-108.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
2 |
| Overweight |
1 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$43.00*
(-21.40% downside)
Low
35.0
Current: 54.71
High
55.0
Target: 43.00
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 54.39 | 25.43 | 10.77 | 2.27 |
| Revenue Growth | 113.89% | 136.16% | 374.53% | - |
| Gross Profit | 6.96 | -6.76 | -13.25 | -7.15 |
| Operating Income | -109 | -70.56 | -58.48 | -43.66 |
| Net Income | -108 | -71.24 | -59.31 | -44.09 |
| Shares Outstanding | 27.46 | 2.79 | 2.42 | 1.87 |
| Earnings Per Share | -3.92 | -25.51 | -24.49 | -23.58 |
| Operating Cash Flow | -87.94 | -66.16 | -51.30 | -38.59 |
| Capital Expenditures | -14.74 | -3.67 | -6.33 | -6.23 |
| Free Cash Flow | -103 | -69.84 | -57.63 | -44.82 |
| Cash & Equivalents | 138 | 80.76 | 62.20 | 55.92 |
| Total Debt | 7.73 | 9.72 | 9.15 | 11.18 |
| Net Cash / Debt | 130 | 71.04 | 53.05 | 44.74 |
| Assets | 187 | 116 | 85.66 | 76.46 |
| Liabilities | 34.91 | 26.73 | 19.38 | 19.04 |
| Book Value | 152 | -201 | -133 | -76.61 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Twist Bioscience Corporation |
| Country |
United States |
| Employees |
414 |
| CEO |
Emily Marine Leproust |
Stock Information
| Ticker Symbol |
TWST |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: TWST |
| IPO Date |
October 31, 2018 |
Description
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. Twist Bioscience Corporation has collaboration agreements with Pandion Therapeutics, Inc. and Schrödinger Inc. It also has a partnership with Serimmune Inc. to identify and evaluate SARS-CoV-2 therapeutic antibody candidates. The company was founded in 2013 and is headquartered in South San Francisco, California.